Teva, Eyeing Follow-Ons For Most Biologics, Starts With Amgen's Neupogen
Executive Summary
Teva is looking into developing follow-on products for most of the biologics currently available on the U.S. market, William S. Marth, president and CEO of Teva North America, said in an interview
You may also be interested in...
Merck Prepares To Test Drive Biosimilar Pathway In The U.S.
Merck is gearing up to test the new regulatory pathway for biosimilar drugs in the U.S. and is hoping to be the first drug maker to move a biologic through the abbreviated process, Merck BioVentures President Michael Kamarck said in an interview June 28
Merck Prepares To Test Drive Biosimilar Pathway In The U.S.
Merck is gearing up to test the new regulatory pathway for biosimilar drugs in the U.S. and is hoping to be the first drug maker to move a biologic through the abbreviated process, Merck BioVentures President Michael Kamarck said in an interview June 28
Sandoz Will Steer Clear Of U.S. Biosimilars Pathway, Use Other Applications
Drug companies looking to bring biosimilars to the U.S. market will use existing regulatory pathways like 505(b)(2) or an outright Biologics Licensing Application over a new regulatory pathway provided in the health care reform legislation because of provisions in the new pathway that favor brands, Jeff George, the head of Sandoz, predicted